AMGN250110C227500
- 0.00
- 0.000.00%
Amgen Newsroom
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $298
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Announces Target Price $298
FDA Issues Draft Guidance on Developing Weight Loss Drugs
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $324
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK
Amgen's IMDYLLTRA▼ (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Piper Sandler has lowered Amgen's Target Price to $310.
Gelonghui, January 2 | Piper Sandler: Downgraded Amgen's Target Price from $344 to $310, maintaining a "Shareholding" rating. (Gelonghui)
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310